Recombinant human activated protein C in sepsis: Inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials
- 1 January 2003
- journal article
- review article
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 31 (Supplement) , S94-S96
- https://doi.org/10.1097/00003246-200301001-00013
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Risk and the Efficacy of Antiinflammatory AgentsAmerican Journal of Respiratory and Critical Care Medicine, 2002
- Recombinant human activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating nuclear factor-κBCritical Care Medicine, 2002
- Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: A multicenter, randomized, placebo-controlled, single-blind, dose escalation studyCritical Care Medicine, 2001
- High-Dose Antithrombin III in Severe SepsisJAMA, 2001
- Severe Sepsis — A New Treatment with Both Anticoagulant and Antiinflammatory PropertiesNew England Journal of Medicine, 2001
- Efficacy and Safety of Recombinant Human Activated Protein C for Severe SepsisNew England Journal of Medicine, 2001